Finasteride pour Alopécie Androgénétique

References

1. [1] Aditya K Gupta et al.. Int J Dermatol. 2026. Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From … doi:10.1111/ijd.17957 PubMed
2. [2] Aditya K Gupta et al.. J Dermatolog Treat. 2026. Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and … doi:10.1080/09546634.2025.2611703 PubMed
3. [3] Kevin T Nguyen et al.. Int J Dermatol. 2026. The Over-The-Counter Finasteride Alternative: A Critical Review of Saw Palmetto's Efficacy, Safety, and Regulatory Concerns. doi:10.1111/ijd.17987 PubMed
4. [4] Daniel Ramos-Rodriguez et al.. Dermatol Ther (Heidelb). 2026. Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review. doi:10.1007/s13555-026-01735-9 PubMed
5. [5] Jacob Beer et al.. Dermatol Surg. 2026. Injectable Therapy for Androgenetic Alopecia: A Systematic Review. doi:10.1097/DSS.0000000000004999 PubMed
6. [6] Zetian Zhong et al.. J Cosmet Dermatol. 2026. Research Progress on Platelet-Rich Plasma (PRP) in the Treatment of Androgenetic Alopecia. doi:10.1111/jocd.70809 PubMed
7. [7] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
8. [8] Ngoc-Trinh Tran et al.. Biomaterials. 2026. A novel cell-free regenerative therapy for hair loss: human fetal cartilage progenitor cell secretome. doi:10.1016/j.biomaterials.2025.123627 PubMed
9. [9] Guorui Li et al.. J Cosmet Dermatol. 2026. Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of Androgenetic Alopecia. doi:10.1111/jocd.70726 PubMed
10. [10] Jovian Wan et al.. Aesthetic Plast Surg. 2025. A Prospective Study of Exosome Therapy for Androgenetic Alopecia. doi:10.1007/s00266-025-04817-9 PubMed
11. [11] Jair Alejandro Valdez-Zertuche et al.. Expert Opin Drug Metab Toxicol. 2025. Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review. doi:10.1080/17425255.2025.2461483 PubMed
12. [12] Jayanaraian F M Andrade et al.. Expert Opin Drug Deliv. 2025. An update on nanocarriers for follicular-targeted drug delivery for androgenetic alopecia topical treatment. doi:10.1080/17425247.2025.2457950 PubMed
13. [13] Ilmari Saarinen et al.. Br J Surg. 2025. Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. doi:10.1093/bjs/znaf132 PubMed
14. [14] Aditya K Gupta et al.. PLoS One. 2025. Epidemiological landscape of androgenetic alopecia in the US: An All of Us cross-sectional study. doi:10.1371/journal.pone.0319040 PubMed
15. [15] Shuting Chen et al.. Drug Des Devel Ther. 2025. Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment. doi:10.2147/DDDT.S542000 PubMed
16. [16] Changpei Lu et al.. Regen Ther. 2025. Platelet-rich plasma-derived exosomes stimulate hair follicle growth through activation of the Wnt/β-Catenin signaling pathway. doi:10.1016/j.reth.2025.04.003 PubMed
17. [17] Gabriel Lazzeri Cortez et al.. An Bras Dermatol. 2025. Male androgenetic alopecia. doi:10.1016/j.abd.2024.08.004 PubMed
18. [18] Xiaoling Zhong et al.. PLoS One. 2025. Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 … doi:10.1371/journal.pone.0309849 PubMed
19. [19] Ziyi Liu et al.. Int J Pharm. 2025. Co-delivery of minoxidil and finasteride via ionic liquid and cyclodextrin-assisted in situ thermosensitive hydrogel for synergistic treatment of androgenic alopecia. doi:10.1016/j.ijpharm.2025.125263 PubMed
20. [20] Simone Cilio et al.. Int J Impot Res. 2025. Post-finasteride syndrome - a true clinical entity? doi:10.1038/s41443-025-01025-6 PubMed
21. [21] Hans Johnson et al.. Cureus. 2025. Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation. doi:10.7759/cureus.77549 PubMed
22. [22] Ping Xue et al.. J Cosmet Dermatol. 2025. A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation for Patients With Androgenetic Alopecia. doi:10.1111/jocd.16665 PubMed
23. [23] Jia Zhi et al.. J Med Chem. 2025. Wnt/β-Catenin Signaling Pathway Targeting Androgenetic Alopecia: How Far Can We Go Beyond Minoxidil and Finasteride? doi:10.1021/acs.jmedchem.5c02108 PubMed
24. [24] Cheng Zhou et al.. Chin Med J (Engl). 2025. Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, … doi:10.1097/CM9.0000000000003495 PubMed
25. [25] Jayanaraian F M Andrade et al.. Ther Deliv. 2025. Topical dutasteride for androgenic alopecia: current state and prospects. doi:10.1080/20415990.2024.2437973 PubMed
26. [26] Aditya K Gupta et al.. J Cosmet Dermatol. 2025. Finasteride Use: Evaluation of Depression and Suicide Risk. doi:10.1111/jocd.70102 PubMed
27. [27] Varalee Sereepanpanich et al.. JAAD Int. 2025. Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, … doi:10.1016/j.jdin.2025.08.009 PubMed
28. [28] Aditya K Gupta et al.. Expert Opin Pharmacother. 2025. Efficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review. doi:10.1080/14656566.2025.2461169 PubMed
29. [29] Shuqi Chen et al.. Eur J Dermatol. 2025. Research progress on the pathogenesis of androgenetic alopecia. doi:10.1684/ejd.2025.4815 PubMed
30. [30] Lili Legiawati et al.. Arch Dermatol Res. 2025. Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups. doi:10.1007/s00403-025-04006-3 PubMed
31. [31] Silvia Diviccaro et al.. Biomolecules. 2025. Exploration of the Possible Relationships Between Gut and Hypothalamic Inflammation and Allopregnanolone: Preclinical Findings in a Post-Finasteride Rat Model. doi:10.3390/biom15071044 PubMed
32. [32] Laxmi Iyengar et al.. Aust Prescr. 2025. Male and female pattern hair loss. doi:10.18773/austprescr.2025.020 PubMed
33. [33] Huixing Zhang et al.. Phytomedicine. 2025. Shen-Ying-Yang-Zhen formula promotes angiogenesis around hair follicles, alleviates oxidative stress, and inhibits hair follicle apoptosis through the VEGF/Akt/Caspase-9 signaling axis. doi:10.1016/j.phymed.2025.156963 PubMed
34. [34] Ambika Nohria et al.. J Am Acad Dermatol. 2025. Treatment of androgenetic alopecia with low-dose oral minoxidil monotherapy compared with combination therapy with dutasteride or finasteride. doi:10.1016/j.jaad.2025.01.067 PubMed
35. [35] Xuexue Pan et al.. Aesthetic Plast Surg. 2025. Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. doi:10.1007/s00266-025-05077-3 PubMed
36. [36] Aditya K Gupta et al.. J Cosmet Dermatol. 2025. Comparative Efficacy of Minoxidil and 5-Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta-Analysis Study of Current Empirical … doi:10.1111/jocd.70320 PubMed
37. [37] Fan Qi et al.. ACS Appl Mater Interfaces. 2025. Plant Nanovesicles Integrate Bioactivity and Transdermal Finasteride Delivery for Androgenetic Alopecia. doi:10.1021/acsami.5c15594 PubMed
38. [38] Behnam Hasannejad-Asl et al.. Front Bioinform. 2025. Computational drug discovery of potential 5α-reductase phytochemical inhibitors and hair growth promotion using in silico techniques. doi:10.3389/fbinf.2025.1570101 PubMed
39. [39] Rui-Xian Guo et al.. Front Pharmacol. 2025. Research progress in the treatment of non-scarring alopecia: mechanism and treatment. doi:10.3389/fphar.2025.1544068 PubMed
40. [40] Farah Faulin Lubis et al.. Arch Dermatol Res. 2025. Randomized controlled trial on the efficacy and safety of the combination therapy of topical 0.1% finasteride - 5% Minoxidil in … doi:10.1007/s00403-025-04216-9 PubMed
41. [41] Ian Landells et al.. J Cutan Med Surg. 2025. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. doi:10.1177/12034754251368849 PubMed
42. [42] Naglaa Mohamad Al Sayed et al.. Dermatol Pract Concept. 2025. Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment. doi:10.5826/dpc.1501a4698 PubMed
43. [43] Zachary Neubauer et al.. J Am Acad Dermatol. 2025. No increased risk of mood disorders in male androgenetic alopecia patients treated with dutasteride and finasteride: A retrospective cohort database … doi:10.1016/j.jaad.2025.03.068 PubMed
44. [44] Aditya K Gupta et al.. Skin Appendage Disord. 2025. Do Non-Prescription Products Help in Managing Androgenic Alopecia? doi:10.1159/000542880 PubMed
45. [45] Miquel Martínez-Navarrete et al.. Eur J Pharm Biopharm. 2025. Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch. doi:10.1016/j.ejpb.2025.114728 PubMed
46. [46] Yusuke Tominaga et al.. J Med Case Rep. 2025. The safety and efficacy of finasteride for transgender men with androgenetic alopecia: a case series. doi:10.1186/s13256-025-05562-y PubMed
47. [47] Massimo Milani et al.. J Cosmet Dermatol. 2025. Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real-Life, Multicenter, Randomized, Assessor-Blinded Trial … doi:10.1111/jocd.70388 PubMed
48. [48] Sherif A Kamar et al.. Cells Tissues Organs. 2025. Exploring Mesenchymal Stem Cells versus Minoxidil for Androgenic Alopecia Treatment: A Detailed Animal-Based Histological and Morphometric Study. doi:10.1159/000542547 PubMed
49. [49] David Broadley et al.. Int J Cosmet Sci. 2025. A proprietary lipidosterolic extract of Serenoa repens promotes hair growth through mechanisms that extend beyond 5-alpha reductase inhibition: Insights from … doi:10.1111/ics.70035 PubMed
50. [50] Stephano Cedirian et al.. Dermatol Ther (Heidelb). 2025. Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic Alopecia: A Pilot Study. doi:10.1007/s13555-025-01532-w PubMed
51. [51] Yinfeng Xia et al.. Front Med (Lausanne). 2025. Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis based on randomized controlled trials. doi:10.3389/fmed.2025.1638496 PubMed
52. [52] Nghiem H Nguyen et al.. J Plast Reconstr Aesthet Surg. 2025. Estrogen hormone therapy stabilizes lateral hairline in transfeminine patients: Implications for facial feminization surgery. doi:10.1016/j.bjps.2024.07.044 PubMed
53. [53] Yan Chang et al.. Arch Dermatol Res. 2025. Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of androgenetic alopecia in males. doi:10.1007/s00403-025-03891-y PubMed
54. [54] Yingzi Liu et al.. Nat Rev Dis Primers. 2025. Androgenetic alopecia. doi:10.1038/s41572-025-00656-9 PubMed
55. [55] Jung-Won Shin et al.. Ann Dermatol. 2025. Updates in Treatment for Androgenetic Alopecia. doi:10.5021/ad.25.042 PubMed
56. [56] Adal Mena-García et al.. Molecules. 2025. Kyoh® Rocket Leaf Extract Regulates Proliferation and VEGF and FGF7 Expression in Human Dermal Follicle Papilla Cells. doi:10.3390/molecules30071489 PubMed
57. [57] Anurak Muangsanguan et al.. Foods. 2025. Anti-Hair Loss Potential of Perilla Seed Extracts: In Vitro Molecular Insights from Supercritical Fluid Extraction. doi:10.3390/foods14152583 PubMed
58. [58] Carolina Schettino Kegele et al.. Int J Pharm Compd. 2025. Personalized Compounded Hair Loss Treatments: A Compatibility Assessment of the TrichoConcept™ Vehicle Line. PubMed
59. [59] Zachary Neubauer et al.. Int J Dermatol. 2025. Similar Risk of Sexual Dysfunction in Androgenetic Alopecia Patients Treated With Dutasteride vs. Finasteride: A Retrospective Cohort Database Study. doi:10.1111/ijd.17887 PubMed
60. [60] Aditya K Gupta et al.. J Cosmet Dermatol. 2025. Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study. doi:10.1111/jocd.70483 PubMed
61. [61] Veerendra Kumar Panuganti et al.. Cureus. 2025. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical … doi:10.7759/cureus.89309 PubMed
62. [62] Robert J Vanaria et al.. J Cosmet Dermatol. 2025. The Use of Light-Based Therapies in the Treatment of Alopecia. doi:10.1111/jocd.70434 PubMed
63. [63] Lei Zhou et al.. Front Nutr. 2025. Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis. doi:10.3389/fnut.2025.1719711 PubMed
64. [64] Dan Liu et al.. Int J Med Sci. 2024. Status of research on the development and regeneration of hair follicles. doi:10.7150/ijms.88508 PubMed
65. [65] Xiaochuan Wu et al.. J Control Release. 2024. Hybrid hair follicle stem cell extracellular vesicles co-delivering finasteride and gold nanoparticles for androgenetic alopecia treatment. doi:10.1016/j.jconrel.2024.07.066 PubMed
66. [66] Alfredo Rossi et al.. J Cosmet Dermatol. 2024. Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic … doi:10.1111/jocd.15953 PubMed
67. [67] Barbara Owecka et al.. Biomedicines. 2024. The Hormonal Background of Hair Loss in Non-Scarring Alopecias. doi:10.3390/biomedicines12030513 PubMed
68. [68] Afsaneh Sadeghzadeh Bazargan et al.. J Cosmet Dermatol. 2024. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … doi:10.1111/jocd.15979 PubMed
69. [69] Yunbu Ding et al.. Dermatology. 2024. Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. doi:10.1159/000541395 PubMed
70. [70] Ilakkia Priya Sadasivam et al.. Indian J Dermatol. 2024. Androgenetic Alopecia in Men: An Update On Genetics. doi:10.4103/ijd.ijd_729_23 PubMed
71. [71] Yuyang Gan et al.. Plast Reconstr Surg. 2024. A Clinical Trial of Treating Androgenic Alopecia with Mesenchymal Stem Cell Suspension Derived from Autologous Hair Follicle. doi:10.1097/PRS.0000000000010841 PubMed
72. [72] S Morteza Seyed Jafari et al.. J Clin Med. 2024. Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. doi:10.3390/jcm13113052 PubMed
73. [73] Amanda Rosenthal et al.. J Cosmet Laser Ther. 2024. Management of androgenic alopecia: a systematic review of the literature. doi:10.1080/14764172.2024.2362126 PubMed
74. [74] Alessandro Uleri et al.. Eur Urol Focus. 2024. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis. doi:10.1016/j.euf.2024.04.009 PubMed
75. [75] Siddhi Bianca Camila Lama et al.. J Clin Med. 2024. Physical Treatments and Therapies for Androgenetic Alopecia. doi:10.3390/jcm13154534 PubMed
76. [76] Aditya K Gupta et al.. J Cosmet Dermatol. 2024. The impact of monotherapies for male androgenetic alopecia: A network meta-analysis study. doi:10.1111/jocd.16362 PubMed
77. [77] Ratchathorn Panchaprateep. Facial Plast Surg. 2024. Medical Treatment for Androgenetic Alopecia. doi:10.1055/a-2196-4713 PubMed
78. [78] Jiratchaya Tantiyavarong et al.. Photodermatol Photoimmunol Photomed. 2024. Red and Green LED Light Therapy: A Comparative Study in Androgenetic Alopecia. doi:10.1111/phpp.13004 PubMed
79. [79] Aditya K Gupta et al.. Expert Opin Emerg Drugs. 2024. Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia. doi:10.1080/14728214.2024.2346590 PubMed
80. [80] MaryAnn Dakkak et al.. Am Fam Physician. 2024. Hair Loss: Diagnosis and Treatment. PubMed
81. [81] Kyle C Lauck et al.. J Am Acad Dermatol. 2024. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study. doi:10.1016/j.jaad.2024.03.019 PubMed
82. [82] Aditya K Gupta et al.. Expert Opin Pharmacother. 2024. Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia. doi:10.1080/14656566.2024.2314087 PubMed
83. [83] Nouf F Bin Rubaian et al.. Clin Cosmet Investig Dermatol. 2024. An Overview of Commonly Used Natural Alternatives for the Treatment of Androgenetic Alopecia, with Special Emphasis on Rosemary Oil. doi:10.2147/CCID.S470989 PubMed
84. [84] Xuehua Ruan et al.. Environ Health. 2024. Maternal multivitamin supplementation mitigates the risk of fetal congenital heart disease associated with high indoor total volatile organic compounds exposure … doi:10.1186/s12940-024-01150-7 PubMed
85. [85] Aditya K Gupta et al.. J Cosmet Dermatol. 2024. The relative effect of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta-analysis study. doi:10.1111/jocd.15910 PubMed
86. [86] Norihisa Kato et al.. Int J Mol Sci. 2024. Does Vitamin B6 Act as an Exercise Mimetic in Skeletal Muscle? doi:10.3390/ijms25189962 PubMed
87. [87] Mahboob Alam et al.. Pharm Nanotechnol. 2024. Development and Evaluation of Dutasteride Nanoemulgel for the Topical Delivery against Androgenic Alopecia. doi:10.2174/0122117385269151231031161411 PubMed
88. [88] Anna Lyakhovitsky et al.. Australas J Dermatol. 2024. The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population-based case-control study. doi:10.1111/ajd.14359 PubMed
89. [89] Almuntsrbellah Almudimeegh et al.. Dermatol Reports. 2024. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic … doi:10.4081/dr.2024.9909 PubMed
90. [90] Sangmin Choi et al.. J Dermatol. 2024. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with … doi:10.1111/1346-8138.17138 PubMed
91. [91] Deesha D Desai et al.. Arch Dermatol Res. 2024. Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. doi:10.1007/s00403-024-03361-x PubMed
92. [92] Xuefei Zhang et al.. Int J Nanomedicine. 2024. Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. doi:10.2147/IJN.S477820 PubMed
93. [93] Nazia Asad et al.. J Drugs Dermatol. 2024. Efficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. doi:10.36849/JDD.7826 PubMed
94. [94] Shivali Devjani et al.. Drugs. 2023. Androgenetic Alopecia: Therapy Update. doi:10.1007/s40265-023-01880-x PubMed
95. [95] Sincengile Ntshingila et al.. JAAD Int. 2023. Androgenetic alopecia: An update. doi:10.1016/j.jdin.2023.07.005 PubMed
96. [96] Michael Kaiser et al.. Clin Cosmet Investig Dermatol. 2023. Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. doi:10.2147/CCID.S385861 PubMed
97. [97] David Saceda-Corralo et al.. Am J Clin Dermatol. 2023. What's New in Therapy for Male Androgenetic Alopecia? doi:10.1007/s40257-022-00730-y PubMed
98. [98] Paulo Müller Ramos et al.. An Bras Dermatol. 2023. Female-pattern hair loss: therapeutic update. doi:10.1016/j.abd.2022.09.006 PubMed
99. [99] Julia L Gao et al.. J Am Acad Dermatol. 2023. Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. doi:10.1016/j.jaad.2021.08.067 PubMed
100. [100] Mariana Escamilla-Cruz et al.. Dermatol Ther (Heidelb). 2023. Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review. doi:10.1007/s13555-023-00974-4 PubMed
101. [101] Nathalie Y Ly et al.. J Am Acad Dermatol. 2023. Medical and procedural treatment of androgenetic alopecia - Where are we? doi:10.1016/j.jaad.2023.05.004 PubMed
102. [102] Parth S Bajoria et al.. Cureus. 2023. Comparing Current Therapeutic Modalities of Androgenic Alopecia: A Literature Review of Clinical Trials. doi:10.7759/cureus.42768 PubMed
103. [103] Brendon Roets. Mater Today Bio. 2023. Potential application of PBM use in hair follicle organoid culture for the treatment of androgenic alopecia. doi:10.1016/j.mtbio.2023.100851 PubMed
104. [104] Ashling Courtney et al.. Expert Opin Pharmacother. 2023. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia. doi:10.1080/14656566.2023.2280630 PubMed
105. [105] Niloufar Najar Nobari et al.. Adv Clin Exp Med. 2023. A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive … doi:10.17219/acem/157990 PubMed
106. [106] Akshunna Keerti et al.. Cureus. 2023. Topical Finasteride: A Comprehensive Review of Androgenetic Alopecia Management for Men and Women. doi:10.7759/cureus.44949 PubMed
107. [107] Dharm Mansukh Sondagar et al.. Int J Trichology. 2023. Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia - A Randomized Controlled Trial. doi:10.4103/ijt.ijt_5_22 PubMed
108. [108] Jeffrey Rapaport et al.. J Drugs Dermatol. 2023. Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia. doi:10.36849/JDD.7403 PubMed
109. [109] Sultan Pulat et al.. Pharmaceutics. 2023. Topical Delivery of Atraric Acid Derived from Stereocaulon japonicum with Enhanced Skin Permeation and Hair Regrowth Activity for Androgenic Alopecia. doi:10.3390/pharmaceutics15020340 PubMed
110. [110] Francielle de Fátima Viana Santana et al.. Toxicol Appl Pharmacol. 2023. Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo … doi:10.1016/j.taap.2023.116710 PubMed
111. [111] Yoshitaka Hobo et al.. Clin Chim Acta. 2023. Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair. doi:10.1016/j.cca.2023.117456 PubMed
112. [112] S Cedirian et al.. J Cosmet Dermatol. 2023. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … doi:10.1111/jocd.15873 PubMed
113. [113] Satyendra K Singh et al.. Indian J Dermatol Venereol Leprol. 2023. Effect of platelet counts and activator in platelet-rich plasma on the treatment of androgenetic alopecia, split-head comparison: A randomised, double-blind … doi:10.25259/IJDVL_1254_20 PubMed
114. [114] Michael A Kaiser et al.. J Cutan Aesthet Surg. 2023. Platelet Rich Plasma Combination Therapies for Treatment of Androgenetic Alopecia: A Systematic Review. doi:10.4103/JCAS.JCAS_206_22 PubMed
115. [115] Francisco José Rodríguez-Cuadrado et al.. Eur J Dermatol. 2023. Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature. doi:10.1684/ejd.2023.4443 PubMed
116. [116] Tiago Fernandes Gomes et al.. J Dtsch Dermatol Ges. 2023. Pediatric androgenetic alopecia: an updated review. doi:10.1111/ddg.14940 PubMed
117. [117] Pooja Agarwal et al.. Int J Trichology. 2023. Platelet-Rich Plasma in Androgenetic Alopecia: Is It Really Worth the Hype? doi:10.4103/ijt.ijt_31_21 PubMed
118. [118] Michela Starace et al.. Ital J Dermatol Venerol. 2023. Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic … doi:10.23736/S2784-8671.22.07416-3 PubMed
119. [119] Shreya Deoghare et al.. J Cosmet Laser Ther. 2023. Combination therapy in female pattern hair loss. doi:10.1080/14764172.2023.2222942 PubMed
120. [120] Li Hu et al.. BMJ Case Rep. 2023. Inverse androgenic alopecia. doi:10.1136/bcr-2022-254361 PubMed
121. [121] Houfar Sekhavat et al.. Int J Trichology. 2023. TH07 - A New Novel Topical Treatment for Androgenic Alopecia. doi:10.4103/ijt.ijt_145_22 PubMed
122. [122] Jordan Sand et al.. Clin Plast Surg. 2023. Noninvasive Hair Rejuvenation. doi:10.1016/j.cps.2022.12.015 PubMed
123. [123] B M Piraccini et al.. J Eur Acad Dermatol Venereol. 2022. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. doi:10.1111/jdv.17738 PubMed
124. [124] Aditya K Gupta et al.. J Dermatolog Treat. 2022. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. doi:10.1080/09546634.2022.2109567 PubMed
125. [125] Aditya K Gupta et al.. JAMA Dermatol. 2022. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. doi:10.1001/jamadermatol.2021.5743 PubMed
126. [126] A K Gupta et al.. J Dermatolog Treat. 2022. Finasteride for hair loss: a review. doi:10.1080/09546634.2021.1959506 PubMed
127. [127] Poonkiat Suchonwanit et al.. J Dermatolog Treat. 2022. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. doi:10.1080/09546634.2020.1782324 PubMed
128. [128] Warintorn Ruksiriwanich et al.. Plants (Basel). 2022. Phytochemical Constitution, Anti-Inflammation, Anti-Androgen, and Hair Growth-Promoting Potential of Shallot (Allium ascalonicum L.) Extract. doi:10.3390/plants11111499 PubMed
129. [129] Dmitri Wall et al.. Fac Rev. 2022. Advances in hair growth. doi:10.12703/r/11-1 PubMed
130. [130] Aditya K Gupta et al.. Dermatol Ther. 2022. Natural products for male androgenetic alopecia. doi:10.1111/dth.15323 PubMed
131. [131] Aditya K Gupta et al.. J Dermatolog Treat. 2022. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment … doi:10.1080/09546634.2020.1749547 PubMed
132. [132] Talagavadi Channaiah Anudeep et al.. Pharmaceutics. 2022. Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia. doi:10.3390/pharmaceutics14030612 PubMed
133. [133] Miguel Garcia-Argibay et al.. JAMA Netw Open. 2022. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide. doi:10.1001/jamanetworkopen.2022.48135 PubMed
134. [134] Aditya K Gupta et al.. J Cosmet Dermatol. 2022. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? doi:10.1111/jocd.14895 PubMed
135. [135] Vanuchawan Wisuitiprot et al.. Sci Rep. 2022. Effects of Acanthus ebracteatus Vahl. extract and verbascoside on human dermal papilla and murine macrophage. doi:10.1038/s41598-022-04966-w PubMed
136. [136] Silvia Tampucci et al.. Pharmaceutics. 2022. Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle. doi:10.3390/pharmaceutics14020286 PubMed
137. [137] Kai Tian et al.. J Cosmet Dermatol. 2022. A study of combination unilateral subcutaneous botulinum toxin a treatment for androgenetic alopecia. doi:10.1111/jocd.15179 PubMed
138. [138] Gwang-Seong Choi et al.. Ann Dermatol. 2022. Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart … doi:10.5021/ad.22.027 PubMed
139. [139] Dong Wook Shin. Korean J Physiol Pharmacol. 2022. The physiological and pharmacological roles of prostaglandins in hair growth. doi:10.4196/kjpp.2022.26.6.405 PubMed
140. [140] Pietro Gentile et al.. J Plast Reconstr Aesthet Surg. 2022. Systematic review: The platelet-rich plasma use in female androgenetic alopecia as effective autologous treatment of regenerative plastic surgery. doi:10.1016/j.bjps.2021.11.004 PubMed
141. [141] Peter R Feldman et al.. Front Med (Lausanne). 2022. Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis. doi:10.3389/fmed.2022.998623 PubMed
142. [142] Daniel Fernandes Melo et al.. Dermatol Ther. 2022. Frontal edema due to mesotherapy for androgenetic alopecia: A case series. doi:10.1111/dth.15247 PubMed
143. [143] E Sánchez-Meza et al.. J Eur Acad Dermatol Venereol. 2022. Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. doi:10.1111/jdv.18285 PubMed
144. [144] Pedro Romero Pérez. Arch Esp Urol. 2022. Post-Finasteride Syndrome. Literature Review. doi:10.56434/j.arch.esp.urol.20227505.56 PubMed
145. [145] Natalie Haddad et al.. J Drugs Dermatol. 2022. Evaluating the Efficacy of Platelet Rich Plasma and 1550 nm Fractional Laser in Combination and Alone for the Management of … doi:10.36849/JDD.6750 PubMed
146. [146] Aye Chan Khine Lin et al.. Sci Rep. 2022. Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and … doi:10.1038/s41598-022-25335-7 PubMed
147. [147] Hua-Ching Chang et al.. J Cosmet Dermatol. 2022. Association between serum zinc levels and androgenetic alopecia: a systematic review and meta-analysis. doi:10.1111/jocd.14564 PubMed
148. [148] Fan Zhang et al.. Clin Cosmet Investig Dermatol. 2022. Observation on the Efficacy of a Combined Treatment for Moderate and Severe Androgenetic Alopecia Incorporating Electric Microneedles. doi:10.2147/CCID.S383289 PubMed
149. [149] Palash Sahu et al.. Cureus. 2022. Biomaterials for Treatment of Baldness. doi:10.7759/cureus.31187 PubMed
150. [150] Alfredo Rossi et al.. Ital J Dermatol Venerol. 2022. A new combination of molecules for the treatment of androgenetic alopecia and telogen effluvium: a double-blind randomized, monocentric, placebo-controlled study. doi:10.23736/S2784-8671.21.06915-7 PubMed
151. [151] Jordan Sand et al.. Facial Plast Surg Clin North Am. 2022. Noninvasive Hair Rejuvenation. doi:10.1016/j.fsc.2022.03.015 PubMed
152. [152] Mark S Nestor et al.. J Cosmet Dermatol. 2021. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. doi:10.1111/jocd.14537 PubMed
153. [153] Jisha K Pillai et al.. J Cutan Aesthet Surg. 2021. Role of Low-Level Light Therapy (LLLT) in Androgenetic Alopecia. doi:10.4103/JCAS.JCAS_218_20 PubMed
154. [154] Jacob Griggs et al.. J Am Acad Dermatol. 2021. Pediatric androgenetic alopecia: A review. doi:10.1016/j.jaad.2019.08.018 PubMed
155. [155] Vani Yepuri et al.. J Cutan Aesthet Surg. 2021. Platelet-Rich Plasma with Microneedling in Androgenetic Alopecia: Study of Efficacy of the Treatment and the Number of Sessions Required. doi:10.4103/JCAS.JCAS_33_20 PubMed
156. [156] Matthew B Harrell et al.. World J Urol. 2021. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. doi:10.1007/s00345-020-03314-9 PubMed
157. [157] Peter R Feldman et al.. EClinicalMedicine. 2021. Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial. doi:10.1016/j.eclinm.2021.100978 PubMed
158. [158] Min-Jeong Kang et al.. J Am Acad Dermatol. 2021. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study. doi:10.1016/j.jaad.2020.04.051 PubMed
159. [159] Katherine York et al.. Expert Opin Pharmacother. 2020. A review of the treatment of male pattern hair loss. doi:10.1080/14656566.2020.1721463 PubMed
160. [160] Pietro Gentile et al.. Int J Mol Sci. 2020. Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy. doi:10.3390/ijms21082702 PubMed
161. [161] Abdulmaged M Traish. Fertil Steril. 2020. Post-finasteride syndrome: a surmountable challenge for clinicians. doi:10.1016/j.fertnstert.2019.11.030 PubMed
162. [162] Silvia Diviccaro et al.. Neurobiol Stress. 2020. Post-finasteride syndrome: An emerging clinical problem. doi:10.1016/j.ynstr.2019.100209 PubMed
163. [163] Wimolsiri Iamsumang et al.. Drug Des Devel Ther. 2020. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date. doi:10.2147/DDDT.S240615 PubMed
164. [164] Rachita Dhurat et al.. Dermatol Ther. 2020. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. doi:10.1111/dth.13379 PubMed
165. [165] Abdulmaged M Traish. World J Mens Health. 2020. Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. doi:10.5534/wjmh.200012 PubMed
166. [166] Yaguang Zhou et al.. Biomed Res Int. 2020. Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia. doi:10.1155/2020/1501893 PubMed
167. [167] Sonia Sofia Ocampo-Garza et al.. Dermatol Ther. 2020. Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature. doi:10.1111/dth.14267 PubMed
168. [168] Julie Robitaille et al.. Gen Comp Endocrinol. 2020. Consequences of steroid-5α-reductase deficiency and inhibition in vertebrates. doi:10.1016/j.ygcen.2020.113400 PubMed
169. [169] Sumel Ashique et al.. Nat Prod Bioprospect. 2020. A Systemic Review on Topical Marketed Formulations, Natural Products, and Oral Supplements to Prevent Androgenic Alopecia: A Review. doi:10.1007/s13659-020-00267-9 PubMed
170. [170] Maira Elizabeth Herz-Ruelas et al.. Skin Appendage Disord. 2020. Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review. doi:10.1159/000510697 PubMed
171. [171] Jaime R Fields et al.. Dermatol Ther. 2020. Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. doi:10.1111/dth.13202 PubMed
172. [172] Yi Zhou et al.. Dermatol Ther. 2020. The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta-analysis. doi:10.1111/dth.13741 PubMed
173. [173] Li Chen et al.. Aesthetic Plast Surg. 2020. The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. doi:10.1007/s00266-020-01621-5 PubMed
174. [174] Dustin H Marks et al.. Am J Clin Dermatol. 2020. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. doi:10.1007/s40257-019-00493-z PubMed
175. [175] Tymon Tai et al.. Facial Plast Surg Clin North Am. 2020. Physiology and Medical Treatments for Alopecia. doi:10.1016/j.fsc.2020.01.004 PubMed
176. [176] Dustin H Marks et al.. Dermatol Clin. 2020. Androgenetic Alopecia in Gender Minority Patients. doi:10.1016/j.det.2019.10.010 PubMed
177. [177] Solmaz Asnaashari et al.. Altern Ther Health Med. 2020. Herbal Medicines For Treatment of Androgenic Alopecia. PubMed
178. [178] Tuo Deng et al.. Urol J. 2020. Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis. doi:10.22037/uj.v16i7.5866 PubMed
179. [179] Mahmoud Makki et al.. J Cosmet Laser Ther. 2020. Evaluation of the effect of autologous platelet-rich plasma on androgenic alopecia. doi:10.1080/14764172.2020.1827150 PubMed
180. [180] Cristina Pindado-Ortega et al.. Skin Appendage Disord. 2020. Prescribing Habits for Androgenic Alopecia among Dermatologists in Spain in 2019-2020: A Cross-Sectional Study. doi:10.1159/000509063 PubMed
181. [181] L Reguero-Del Cura et al.. Actas Dermosifiliogr (Engl Ed). 2020. RF-Mesotherapy With Dutasteride: A Future Alternative Treatment for Androgenetic Alopecia. doi:10.1016/j.ad.2018.10.030 PubMed
182. [182] Tatiele Katzer et al.. Dermatol Ther. 2019. Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. doi:10.1111/dth.13059 PubMed
183. [183] J Stevens et al.. Int J Womens Dermatol. 2019. Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. doi:10.1016/j.ijwd.2018.08.004 PubMed
184. [184] Maria Yusuf Dhariwala et al.. J Cosmet Dermatol. 2019. An overview of herbal alternatives in androgenetic alopecia. doi:10.1111/jocd.12930 PubMed
185. [185] Amanda Bienenfeld et al.. J Am Acad Dermatol. 2019. Androgens in women: Androgen-mediated skin disease and patient evaluation. doi:10.1016/j.jaad.2018.08.062 PubMed
186. [186] Solam Lee et al.. Acta Derm Venereol. 2019. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. doi:10.2340/00015555-3035 PubMed
187. [187] Zhongbao Zhou et al.. Clin Interv Aging. 2019. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. doi:10.2147/CIA.S192435 PubMed
188. [188] Sarah Azarchi et al.. J Am Acad Dermatol. 2019. Androgens in women: Hormone-modulating therapies for skin disease. doi:10.1016/j.jaad.2018.08.061 PubMed
189. [189] Yu Seob Shin et al.. World J Mens Health. 2019. Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. doi:10.5534/wjmh.180029 PubMed
190. [190] Enis Rauf Coskuner et al.. Sex Med Rev. 2019. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. doi:10.1016/j.sxmr.2018.07.003 PubMed
191. [191] Jukkarin Srivilai et al.. Assay Drug Dev Technol. 2019. Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors. doi:10.1089/adt.2018.870 PubMed
192. [192] Radosław B Maksym et al.. Aging Male. 2019. Post-finasteride syndrome - does it really exist? doi:10.1080/13685538.2018.1548589 PubMed
193. [193] Angela Wipf et al.. J Cosmet Laser Ther. 2019. The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards … doi:10.1080/14764172.2018.1525743 PubMed
194. [194] Eduardo Anitua et al.. J Cosmet Dermatol. 2019. Platelet rich plasma for the management of hair loss: Better alone or in combination? doi:10.1111/jocd.12683 PubMed
195. [195] Robert S English et al.. Dermatol Ther (Heidelb). 2019. Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results. doi:10.1007/s13555-019-0281-6 PubMed
196. [196] Buse Güler et al.. J Perinat Med. 2019. An investigation of vitamin and mineral supplement recommendation among first-trimester pregnancies. doi:10.1515/jpm-2019-0178 PubMed
197. [197] Karolina Kozicka et al.. Pol Merkur Lekarski. 2019. Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. PubMed
198. [198] V Kanti et al.. J Eur Acad Dermatol Venereol. 2018. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. doi:10.1111/jdv.14624 PubMed
199. [199] G Fabbrocini et al.. Int J Womens Dermatol. 2018. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. doi:10.1016/j.ijwd.2018.05.001 PubMed
200. [200] Sung Won Lee et al.. J Drugs Dermatol. 2018. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. PubMed
201. [201] P Suchonwanit et al.. J Eur Acad Dermatol Venereol. 2018. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil … doi:10.1111/jdv.15171 PubMed
202. [202] Bu Young Choi. Int J Mol Sci. 2018. Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms. doi:10.3390/ijms19092703 PubMed
203. [203] A K Gupta et al.. J Eur Acad Dermatol Venereol. 2018. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. doi:10.1111/jdv.15081 PubMed
204. [204] Lizeth Martinez-Jacobo et al.. Indian J Dermatol Venereol Leprol. 2018. Genetic and molecular aspects of androgenetic alopecia. doi:10.4103/ijdvl.IJDVL_262_17 PubMed
205. [205] Evan Darwin et al.. Lasers Med Sci. 2018. Low-level laser therapy for the treatment of androgenic alopecia: a review. doi:10.1007/s10103-017-2385-5 PubMed
206. [206] Motomu Manabe et al.. J Dermatol. 2018. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. doi:10.1111/1346-8138.14470 PubMed
207. [207] Ion G Motofei et al.. Expert Opin Drug Saf. 2018. Androgenetic alopecia; drug safety and therapeutic strategies. doi:10.1080/14740338.2018.1430765 PubMed
208. [208] Erkin Pekmezci et al.. Med Arch. 2018. Proprietary Herbal Extract Downregulates the Gene Expression of IL-1α in HaCaT Cells: Possible Implications Against Nonscarring Alopecia. doi:10.5455/medarh.2018.72.136-140 PubMed
209. [209] Ibrahim Najem et al.. J Cosmet Laser Ther. 2018. Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. doi:10.1080/14764172.2017.1400174 PubMed
210. [210] C Pindado-Ortega et al.. Actas Dermosifiliogr (Engl Ed). 2018. Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. doi:10.1016/j.ad.2018.02.006 PubMed
211. [211] Ji Hyun Lee et al.. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2018. Determination of illegal adulteration of dietary supplements with synthetic hair-growth compounds by UPLC and LC-Q-TOF/MS. doi:10.1080/19440049.2017.1401736 PubMed
212. [212] Francesca Lolli et al.. Endocrine. 2017. Androgenetic alopecia: a review. doi:10.1007/s12020-017-1280-y PubMed
213. [213] Areej Adil et al.. J Am Acad Dermatol. 2017. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. doi:10.1016/j.jaad.2017.02.054 PubMed
214. [214] Esther J van Zuuren et al.. JAMA Dermatol. 2017. Interventions for Female Pattern Hair Loss. doi:10.1001/jamadermatol.2016.5790 PubMed
215. [215] Sujit J S Shanshanwal et al.. Indian J Dermatol Venereol Leprol. 2017. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled … doi:10.4103/0378-6323.188652 PubMed
216. [216] Tasleem Arif et al.. Curr Clin Pharmacol. 2017. Dutasteride in Androgenetic Alopecia: An Update. doi:10.2174/1574884712666170310111125 PubMed
217. [217] Raymond M Fertig et al.. Dermatol Online J. 2017. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. PubMed
218. [218] Abdulmaged M Traish. Adv Exp Med Biol. 2017. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. doi:10.1007/978-3-319-70178-3_22 PubMed
219. [219] Rachita Dhurat et al.. Skin Pharmacol Physiol. 2017. An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male … doi:10.1159/000481141 PubMed
220. [220] Aditya K Gupta et al.. Dermatol Surg. 2017. A Critical Assessment of the Evidence for Low-Level Laser Therapy in the Treatment of Hair Loss. doi:10.1097/DSS.0000000000000904 PubMed
221. [221] S Vañó-Galván et al.. Actas Dermosifiliogr. 2017. New Treatments for Hair Loss. doi:10.1016/j.ad.2016.11.010 PubMed
222. [222] Ho Won Kang et al.. J Urol. 2017. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride … doi:10.1016/j.juro.2017.07.075 PubMed
223. [223] Ph Paquet et al.. Rev Med Liege. 2017. [What is the value of low-energie lasers in the treatment of androgenetic alopecia ?]. PubMed
224. [224] Hans Wolff et al.. Dtsch Arztebl Int. 2016. The Diagnosis and Treatment of Hair and Scalp Diseases. doi:10.3238/arztebl.2016.0377 PubMed
225. [225] Jukkarin Srivilai et al.. Steroids. 2016. A new label-free screen for steroid 5α-reductase inhibitors using LC-MS. doi:10.1016/j.steroids.2016.10.007 PubMed
226. [226] Sushilkumar Ramdasi et al.. J Stem Cells. 2016. Human Mesenchymal Stem Cell-Derived Conditioned Media for Hair Regeneration Applications. PubMed
227. [227] Esther J van Zuuren et al.. Cochrane Database Syst Rev. 2016. Interventions for female pattern hair loss. doi:10.1002/14651858.CD007628.pub4 PubMed
228. [228] Anita K Gupta et al.. Indian J Pharmacol. 2016. Atypical post-finasteride syndrome: A pharmacological riddle. doi:10.4103/0253-7613.182898 PubMed
229. [229] Abdulmaged M Traish et al.. Rev Endocr Metab Disord. 2015. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? doi:10.1007/s11154-015-9319-y PubMed
230. [230] Rachita Dhurat et al.. Indian J Dermatol. 2015. Response to Microneedling Treatment in Men with Androgenetic Alopecia Who Failed to Respond to Conventional Therapy. doi:10.4103/0019-5154.156361 PubMed
231. [231] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
232. [232] Fernanda Torres et al.. Semin Cutan Med Surg. 2015. Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. doi:10.12788/j.sder.2015.0142 PubMed
233. [233] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
234. [234] H Wolff. Internist (Berl). 2015. [Drug treatment of alopecia]. doi:10.1007/s00108-015-3763-3 PubMed
235. [235] Pinar Avci et al.. Lasers Surg Med. 2014. Low-level laser (light) therapy (LLLT) for treatment of hair loss. doi:10.1002/lsm.22170 PubMed
236. [236] Swapna S Khatu et al.. J Cutan Aesthet Surg. 2014. Platelet-rich plasma in androgenic alopecia: myth or an effective tool. doi:10.4103/0974-2077.138352 PubMed
237. [237] Walter Gubelin Harcha et al.. J Am Acad Dermatol. 2014. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride … doi:10.1016/j.jaad.2013.10.049 PubMed
238. [238] Ruchy Jain et al.. Expert Opin Ther Targets. 2014. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. doi:10.1517/14728222.2014.922956 PubMed
239. [239] Aditya K Gupta et al.. J Dermatolog Treat. 2014. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. doi:10.3109/09546634.2013.813011 PubMed
240. [240] Young Hye Cho et al.. Evid Based Complement Alternat Med. 2014. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. doi:10.1155/2014/549721 PubMed
241. [241] Andréia Munck et al.. Int J Trichology. 2014. Use of low-level laser therapy as monotherapy or concomitant therapy for male and female androgenetic alopecia. doi:10.4103/0974-7753.138584 PubMed
242. [242] Leyre Falto-Aizpurua et al.. Expert Opin Emerg Drugs. 2014. Emerging treatments in alopecia. doi:10.1517/14728214.2014.974550 PubMed
243. [243] Jae Yoon Jung et al.. Int J Dermatol. 2014. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. doi:10.1111/ijd.12060 PubMed
244. [244] Ids H Boersma et al.. Indian J Dermatol Venereol Leprol. 2014. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. doi:10.4103/0378-6323.144162 PubMed
245. [245] Elizabeth Yim et al.. Curr Opin Endocrinol Diabetes Obes. 2014. 5α-Reductase inhibitors in androgenetic alopecia. doi:10.1097/MED.0000000000000112 PubMed
246. [246] Shannon Famenini et al.. J Drugs Dermatol. 2014. Evidence for supplemental treatments in androgenetic alopecia. PubMed
247. [247] B M Piraccini et al.. G Ital Dermatol Venereol. 2014. Androgenetic alopecia. PubMed
248. [248] Feroze Kaliyadan et al.. Indian J Dermatol Venereol Leprol. 2013. Androgenetic alopecia: an update. doi:10.4103/0378-6323.116730 PubMed
249. [249] Nusrat Banka et al.. Dermatol Clin. 2013. Pattern hair loss in men: diagnosis and medical treatment. doi:10.1016/j.det.2012.08.003 PubMed
250. [250] Nattaya Lourith et al.. J Cosmet Dermatol. 2013. Hair loss and herbs for treatment. doi:10.1111/jocd.12051 PubMed
251. [251] Landon Trost et al.. Sex Med Rev. 2013. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. doi:10.1002/smrj.3 PubMed
252. [252] Aron G Nusbaum et al.. Facial Plast Surg Clin North Am. 2013. Nonsurgical therapy for hair loss. doi:10.1016/j.fsc.2013.04.003 PubMed
253. [253] Faris Azzouni et al.. J Drugs Dermatol. 2013. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders. PubMed
254. [254] Hammad A Bhatti et al.. J Cosmet Dermatol. 2013. Hair restoration approaches for early onset male androgenetic alopecia. doi:10.1111/jocd.12047 PubMed
255. [255] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
256. [256] K J McElwee et al.. Skin Therapy Lett. 2012. Promising therapies for treating and/or preventing androgenic alopecia. PubMed
257. [257] A Rossi et al.. Int J Immunopathol Pharmacol. 2012. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. doi:10.1177/039463201202500435 PubMed
258. [258] Olga Boychenko et al.. Cutis. 2012. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. PubMed
259. [259] R Sinclair et al.. Br J Dermatol. 2011. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. doi:10.1111/j.1365-2133.2011.10630.x PubMed
260. [260] Sridar Chittur et al.. Evid Based Complement Alternat Med. 2011. Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic Acid and saw palmetto extract. doi:10.1093/ecam/nep102 PubMed
261. [261] A W Rafi et al.. ISRN Dermatol. 2011. Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. doi:10.5402/2011/241953 PubMed
262. [262] Patrick Henry McDonough et al.. Cutis. 2011. Adolescent androgenic alopecia. PubMed
263. [263] Deepani Rathnayake et al.. Expert Opin Pharmacother. 2010. Male androgenetic alopecia. doi:10.1517/14656561003752730 PubMed
264. [264] Mahyar Ghanaat. South Med J. 2010. Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. doi:10.1097/SMJ.0b013e3181ebcf71 PubMed
265. [265] Eric S Schweiger et al.. J Drugs Dermatol. 2010. Update on the pathogenesis, genetics and medical treatment of patterned hair loss. PubMed
266. [266] Adel Alsantali et al.. Curr Opin Endocrinol Diabetes Obes. 2009. Androgens and hair loss. doi:10.1097/med.0b013e32832b100a PubMed
267. [267] Francisco M Camacho-Martínez. Semin Cutan Med Surg. 2009. Hair loss in women. doi:10.1016/j.sder.2009.01.001 PubMed
268. [268] Anne L Mounsey et al.. Am Fam Physician. 2009. Diagnosing and treating hair loss. PubMed
269. [269] Satoshi Itami. Nihon Rinsho. 2008. [Hair follicle regeneration]. PubMed
270. [270] Noah Scheinfeld. Dermatol Online J. 2008. A review of hormonal therapy for female pattern (androgenic) alopecia. PubMed
271. [271] Nina Otberg et al.. Endocrinol Metab Clin North Am. 2007. Androgenetic alopecia. doi:10.1016/j.ecl.2007.03.004 PubMed
272. [272] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
273. [273] Dow Stough et al.. Mayo Clin Proc. 2005. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. doi:10.4065/80.10.1316 PubMed
274. [274] Martina Bienová et al.. Acta Dermatovenerol Alp Pannonica Adriat. 2005. Androgenetic alopecia and current methods of treatment. PubMed
275. [275] Malgorzata Olszewska et al.. J Drugs Dermatol. 2005. Effective treatment of female androgenic alopecia with dutasteride. PubMed
276. [276] B S Hugo Perez. Med Hypotheses. 2004. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. doi:10.1016/s0306-9877(03)00264-0 PubMed
277. [277] V del Marmol et al.. Rev Med Brux. 2004. [Androgenetic alopecia]. PubMed
278. [278] R M Trüeb. Praxis (Bern 1994). 2003. [Hair loss]. doi:10.1024/0369-8394.92.36.1488 PubMed
279. [279] Karyn Springer et al.. Am Fam Physician. 2003. Common hair loss disorders. PubMed
280. [280] Sujay Khandpur et al.. J Dermatol. 2002. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. doi:10.1111/j.1346-8138.2002.tb00314.x PubMed
281. [281] Keith D Kaufman. Mol Cell Endocrinol. 2002. Androgens and alopecia. doi:10.1016/s0303-7207(02)00372-6 PubMed
282. [282] Justine A Ellis et al.. Expert Rev Mol Med. 2002. Androgenetic alopecia: pathogenesis and potential for therapy. doi:10.1017/S1462399402005112 PubMed
283. [283] J McMurray et al.. Eur J Heart Fail. 2001. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. doi:10.1016/s1388-9842(01)00173-8 PubMed
284. [284] V M Meidan et al.. Drugs. 2001. Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. doi:10.2165/00003495-200161010-00006 PubMed
285. [285] C Bolduc et al.. Am J Clin Dermatol. 2000. Management of androgenetic alopecia. doi:10.2165/00128071-200001030-00002 PubMed
286. [286] D J Hogan et al.. South Med J. 2000. Male pattern baldness. PubMed
287. [287] L Drake et al.. J Am Acad Dermatol. 1999. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. PubMed
288. [288] J L Roberts et al.. J Am Acad Dermatol. 1999. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. PubMed
289. [289] E Diamanti-Kandarakis. Curr Pharm Des. 1999. Current aspects of antiandrogen therapy in women. PubMed
290. [290] A Tosti et al.. Int J Dermatol. 1999. Androgenetic alopecia. doi:10.1046/j.1365-4362.1999.00002.x PubMed
291. [291] D T Scow et al.. Am Fam Physician. 1999. Medical treatments for balding in men. PubMed
292. [292] A Tosti et al.. J Eur Acad Dermatol Venereol. 1999. Management of androgenetic alopecia. PubMed
293. [293] M E Sawaya. J Cutan Med Surg. 1999. Androgenetic alopecia: overview. PubMed
294. [294] T F Cash. Br J Dermatol. 1999. The psychosocial consequences of androgenetic alopecia: a review of the research literature. doi:10.1046/j.1365-2133.1999.03030.x PubMed
295. [295] K D Kaufman et al.. J Am Acad Dermatol. 1998. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. doi:10.1016/s0190-9622(98)70007-6 PubMed
296. [296] J Shapiro et al.. Dermatol Clin. 1998. Hair regrowth. Therapeutic agents. doi:10.1016/s0733-8635(05)70017-6 PubMed
297. [297] E Esteve et al.. Ann Dermatol Venereol. 1997. [Androgenetic alopecia]. PubMed